| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5246925 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
Oct, 2012
(11 years ago) | |
| US5587497 | ABBVIE | 19-nor-vitamin D compounds |
Dec, 2013
(10 years ago) | |
|
US5587497 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds |
Jun, 2014
(9 years ago) | |
| US5597815 | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jul, 2015
(8 years ago) | |
|
US5597815 (Pediatric) | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jan, 2016
(8 years ago) | |
| US6361758 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
| US6136799 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
|
US6361758 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) | |
|
US6136799 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) | |
Zemplar is owned by Abbvie.
Zemplar contains Paricalcitol.
Zemplar has a total of 9 drug patents out of which 9 drug patents have expired.
Expired drug patents of Zemplar are:
- US5246925*PED
- US5587497
- US5587497*PED
- US5597815
- US5597815*PED
- US6361758
- US6136799
- US6361758*PED
- US6136799*PED
Zemplar was authorised for market use on 26 May, 2005.
Zemplar is available in capsule;oral, solution;intravenous dosage forms.
Zemplar can be used as prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 5, which may result in renal osteodystrophy, while avoiding hyperphosphatemia.
The generics of Zemplar are possible to be released after 18 October, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 18, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2023 |
| New Indication(I-599) | Jun 29, 2012 |
| Orphan Drug Exclusivity(ODE-125) | Oct 18, 2023 |
Drugs and Companies using PARICALCITOL ingredient
Market Authorisation Date: 26 May, 2005
Treatment: Prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 5, which may result in renal osteodystrophy, while avoiding hyperphosphatemia
Dosage: CAPSULE;ORAL; SOLUTION;INTRAVENOUS
ZEMPLAR family patents
